先前治疗过晚期胆道癌症患者的临床结局:元分析
Mayur M Amonkar1, Lauren A Abderhalden2, Grace E Fox3
1Merck & Co., Inc., Rahway, NJ 07065, USA.
Future oncology (London, England)
|February 14, 2024
概括
对于先前接受过治疗的晚期胆道癌 (BTC) 患者,传统治疗的有效性很差. 需要新的治疗方法来改善这些患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
背景情况:
- 晚期胆道癌 (BTC) 是一个重大的治疗挑战,特别是在先前治疗进展的患者中.
- 对于初始治疗后无法切除和/或转移的BTC患者,存在有限的治疗选择.
研究的目的:
- 系统地审查和对先前治疗过的晚期胆道癌症 (BTC) 患者的现有治疗方法的疗效进行元分析.
- 确定这些患者的客观应答率 (ORR),中位数整体存活率 (OS) 和中位数无进展存活率 (PFS).
主要方法:
- 对31项研究进行了系统审查和元分析.
- 研究包括了先进 (无法切除和/或转移) BTC 的患者,这些患者在先前的治疗中已经进展.
- 随机效应元分析被用来汇集ORR,中位数OS和中位数PFS的估计.
主要成果:
- 综合的客观响应率 (ORR) 为6.9%.
- 平均整体存活时间 (OS) 为6.6个月.
- 无进展生存期 (PFS) 的中位数为3.2个月.
结论:
- 传统的治疗方法在先前接受治疗的高级BTC患者中表现不佳.
- 发展和实施新型治疗策略以改善患者的治疗结果至关重要.
相关概念视频
Cancer Survival Analysis
346
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
346
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K


